Clinical Trials
9 trialsNCT06959537 2026-05-20
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05723055 2026-05-08
NAHL
University of Utah
Phase 2 Active not recruiting
NCT05491226 2026-04-20
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT07015853 2026-04-20
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting
NCT07349771 2026-04-16
Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
Mayo Clinic
Phase 2 Not yet recruiting
NCT07511062 2026-04-06
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Northside Hospital, Inc.
Phase 1 Not yet recruiting
NCT04710576 2026-03-16
AGAVE-201
Syndax Pharmaceuticals
Phase 2 Active not recruiting
NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT06523556 2026-03-13
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting